← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalNew or expanded indicationCutaneous squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with locally advanced cutaneous squamous cell carcinoma that cannot be cured with surgery or radiation.

LAMPGEN ANALYSIS

Why it matters

The action broadens pembrolizumab to a locally advanced skin cancer population defined by available curative treatment options.

What research teams should watch

Retain the multidisciplinary decision on whether surgery or radiation is curative and document local extent.

PRIMARY RECORDS

Sources